Search

Your search keyword '"PISCAGLIA, FABIO"' showing total 10 results
Start Over Author "PISCAGLIA, FABIO" Journal liver cancer
10 results on '"PISCAGLIA, FABIO"'

1. Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

Author

Iavarone, Massimo, primary, Alimenti, Eleonora, additional, Tada, Toshifumi, additional, Shimose, Shigeo, additional, Suda, Goki, additional, Yoo, Changhoon, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Tosetti, Giulia, additional, Marra, Fabio, additional, Vivaldi, Caterina, additional, Conti, Fabio, additional, Schirripa, Marta, additional, Iwamoto, Hideki, additional, Sho, Takuya, additional, Lee, So Heun, additional, Rizzato, Mario Domenico, additional, Tonnini, Matteo, additional, Rimini, Margherita, additional, Campani, Claudia, additional, Masi, Gianluca, additional, Foschi, Francesco, additional, Bruccoleri, Mariangela, additional, Kawaguchi, Takumi, additional, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Atsukawa, Masanori, additional, Fukunishi, Shinya, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Casadei-Gardini, Andrea, additional, and Lampertico, Pietro, additional

Published
2023
Full Text
View/download PDF

2. Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?

Author

Ravaioli, Matteo, primary, Piscaglia, Fabio, additional, Cillo, Umberto, additional, Brandi, Giovanni, additional, Sessa, Maurizio, additional, Germinario, Giuliana, additional, Golfieri, Rita, additional, Cappelli, Alberta, additional, Morelli, Maria C., additional, Siniscalchi, Antonio, additional, D’Errico, Antonietta, additional, Cescon, Matteo, additional, Iannone, Primiano, additional, and Trevisani, Franco, additional

Published
2021
Full Text
View/download PDF

3. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Author

Tovoli, Francesco, primary, Dadduzio, Vincenzo, additional, De Lorenzo, Stefania, additional, Rimassa, Lorenza, additional, Masi, Gianluca, additional, Iavarone, Massimo, additional, Marra, Fabio, additional, Garajova, Ingrid, additional, Brizzi, Maria Pia, additional, Daniele, Bruno, additional, Trevisani, Franco, additional, Messina, Carlo, additional, Di Clemente, Francesco, additional, Pini, Sara, additional, Cabibbo, Giuseppe, additional, Granito, Alessandro, additional, Rizzato, Mario Domenico, additional, Zagonel, Vittorina, additional, Brandi, Giovanni, additional, Pressiani, Tiziana, additional, Federico, Piera, additional, Vivaldi, Caterina, additional, Bergna, Irene, additional, Campani, Claudia, additional, and Piscaglia, Fabio, additional

Published
2021
Full Text
View/download PDF

4. Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis

Author

Tovoli, Francesco, primary, Guerra, Pietro, additional, Iavarone, Massimo, additional, Veronese, Letizia, additional, Renzulli, Matteo, additional, De Lorenzo, Stefania, additional, Benevento, Francesca, additional, Brandi, Giovanni, additional, Stefanini, Federico, additional, and Piscaglia, Fabio, additional

Published
2020
Full Text
View/download PDF

5. Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT

Author

Finn, Richard S., Qin, Shukui, Piscaglia, Fabio, Evans, Thomas R. Jeffry, Knox, Jennifer J., López López, Carlos, Ramji, Zahra, Ren, Min, Mody, Kalgi, Vogel, Arndt, and Kudo, Masatoshi

Abstract

Introduction:In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs. 12.3 months; HR 0.92, 95% CI 0.79–1.06). The objective response rate (ORR) with lenvatinib was 18.8% by blinded independent imaging review (IIR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); per modified RECIST (mRECIST), the ORR was 40.6%. We sought to further characterize these tumor responses and explore ORR’s importance among outcomes for patients with HCC. Methods:Efficacy assessments included all patients randomly assigned to receive lenvatinib treatment (if bodyweight ≥60 kg, 12 mg/day; if <60 kg, 8 mg/day). Time to first objective response (TTR) and duration of response (DOR) included patients who achieved a partial or complete tumor response. Tumors were assessed by IIR per RECIST v1.1 or mRECIST. Results:Four hundred seventy-eight patients were randomly assigned to receive lenvatinib. By IIR, 90 patients (18.8%) achieved an objective response per RECIST v1.1, and 194 (40.6%) had an objective response per mRECIST. Median TTR/DOR were 2.8 months/7.4 months in responders per RECIST v1.1, and 1.9 months/7.3 months in responders per mRECIST, respectively. Per baseline disease characteristics, ORRs by Child-Pugh score (A5/A6) were 21.2%/11.2% per RECIST v1.1 and 42.9%/33.6% per mRECIST, respectively. By baseline alpha-fetoprotein level (<400/≥400 ng/mL), ORRs were 21.4%/15.4% per RECIST v1.1 and 45.6%/33.8% per mRECIST, respectively. Incidences of treatment-related treatment-emergent adverse events were 98.9% in responders per RECIST v1.1 and 97.9% in responders per mRECIST. Conclusions:Responses were seen even in those patients with more severe disease at baseline. Tumor responses occurred early and were durable.

Published
2024
Full Text
View/download PDF

10. Imaging Diagnosis of Hepatocellular Carcinoma: Recent Advances of Contrast-Enhanced Ultrasonography with SonoVue®

Author

Salvatore, Veronica, Gianstefani, Alice, Negrini, Giulia, Allegretti, Giulia, Galassi, Marzia, and Piscaglia, Fabio

Abstract

AbstractDue to the ability to detect the typical contrast-imaging pattern for hepatocellular carcinoma (HCC), that is hyperenhancement in the arterial phase and hypoenhancement in the late phase on a cirrhotic background, contrast-enhanced ultrasonography (CEUS) was included in the American diagnostic algorithm for HCC in 2005. However, its role has been questioned because of the possibility of misdiagnosis of cholangiocarcinoma. The present review aims to describe the advantages and disadvantages of CEUS applications using Sonovue® for HCC. In particular there is focus on the accuracy of CEUS in detecting the typical HCC pattern, the CEUS patterns of intrahepatic cholangiocarcinoma (ICC), the risk of misdiagnosis with HCC, the diagnostic use of CEUS in cases of locoregional and systemic treatments, and the evaluation of response to antiangiogenic treatment using dedicated software.© 2015 S. Karger AG, Basel

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results